We recently published a list of 10 Best Medical Stocks to Buy According to Billionaires. In this article, we are going to ...

BofA lowered the firm’s price target on Danaher (DHR) to $230 from $265 and keeps a Buy rating on the shares. Sentiment for Life Sciences and ...

Andvari Associates, an investment management firm, released its first-quarter 2025 investor letter. A copy of the letter can ...

Artisan Partners, an investment management company, released its “Artisan Global Opportunities Fund” fourth quarter 2024 ...

Danaher Corp. closed 33.00% below its 52-week high of $281.70, which the company achieved on August 1st.

Danaher Corp. closed 35.83% below its 52-week high of $281.70, which the company reached on August 1st.

Danaher Corporation incorporates science and technology and has a market cap of $150B. The company has mixed financials, with its gross profit margin being its strongest and most consistent.

Growth Drivers include demand for protein-based drugs, rise in chronic disease prevalence, precision medicine expansion, biotech advancements, and AI-driven design tools.Dublin, April 14, 2025 (GLOBE ...

In this article, we are going to take a look at where Danaher Corporation (NYSE:DHR) stands against the other best diagnostics stocks to invest in right now. According to a report by Mordor ...

In this article, we are going to take a look at where Danaher Corporation (NYSE:DHR) stands against other best healthcare stocks to invest in. Healthcare stocks experienced a challenging year in ...

Barclays analyst Luke Sergott upgraded Danaher (DHR – Research Report) to a Buy today and set a price target of $205.00. The company’s shares ...

We recently published a list of Top 10 Stocks to Buy According to Akre Capital Management. In this article, we are going to take a look at where Danaher Corporation (NYSE:DHR) stands against other top ...